Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Shots:

• Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal’s NeXosome platform with Thermo Fisher’s LC-MS instrumentation for monitoring the maternal & fetal health and evaluating the risk of complications
• The focus of the collaboration is to provide a diagnostic solution to both clinical and medical professionals by evaluating maternal and fetal biomarkers during pregnancy and to assess adverse outcomes including preterm birth and preeclampsia for improving health
• NX Prenatal’s NeXosome technology harvest microparticles (exosomes) from the mother’s blood, maintaining the balance between mother & fetus during the pregnancy

Click here to read full press release/ article | Ref: Thermo Fisher | Image: Evaluating Pharma